trial

Nicotinic Receptors and Schizophrenia

NCTId NCT00952393
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 1 · Completed
Enrollment 10 (actual)
Sponsored by VA Office of Research and Development
Primary completion 2014-10
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 1
Status
Completed
Enrollment
10 (actual)
Study type
Interventional
Allocation
Na
Model
Single Group
Masking
None
Start
2010-01
Primary completion
2014-10
Eligibility
ALL · 18 Years · 65 Years

Interventions & indications

Drugs
Pharmacokinetic

Sponsors

VA Office of Research and DevelopmentLead Sponsor

Investigators

1
Robert Freedman, MDPrincipal Investigator

Sites

1 total
Denver, United States

Facts & assertions

4 sourced
Enrollment
10
Phase
PHASE1
Primary Completion Date
2014-10
Status
COMPLETED
relationships
The graph out of here
drug
Pharmacokinetic
drug
lead_sponsor
VA Office of Research and Development
company
indication
Schizophrenia
indication
Schizophrenia
indication
investigator
Robert Freedman, MD
person